New Long-Acting clotting drug could cut bleeding episodes in hemophilia b
NCT ID NCT06399289
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This phase 3 trial tests a long-acting clotting factor (rIX-FP) in 23 Chinese men with severe hemophilia B. The drug is given regularly to prevent bleeding episodes. Researchers will measure how well it works, how long it lasts in the body, and check for side effects like allergic reactions or inhibitors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rIX-FP (a clotting factor IX fused with albumin, brand name Idelvion)
- What this could lead to
- If successful, this could provide a longer-lasting treatment option for hemophilia B, reducing the frequency of injections needed to prevent bleeding episodes.
- What could go wrong
- This is a small, open-label trial in Chinese patients only, so results may not apply broadly. There is a risk of allergic reactions or developing inhibitors that block the treatment's effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, 550004, China
-
Beijing Children's Hospital
Beijing, Beijing Municipality, 100045, China
-
Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
Jinan Central Hospital
Jinan, Shandong, 250013, China
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
-
North China University Of Science And Technology Affiliated Hospital
Tangshan, Hebei, 63000, China
-
Union Hospital Affiliated to Fujian Medical University
Fuzhou, Fujian, 350001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Gene Editing's lasting impact: a 10-Year safety watch
- Can a single gene shot free hemophilia b patients from regular infusions?
- Can a video call replace the clinic for hemophilia pain relief?
- Newborn screening study aims to catch rare diseases at birth
- Monthly shot could free kids with hemophilia from frequent infusions